Once-monthly efimosfermin alfa in participants with metabolic dysfunction-associated steatohepatitis with F2/F3 fibrosis: post hoc results from a 24-week, randomized, double-blind, placebo-controlled, phase 2 trial

efimosfermin alfa (GSK6519754) - GSK

https://events-distribution.easl.eu/from.storage?image=X9WvFraREucXDOc3lNmAYMceZPSPgkj3QVSUchH5pXa3BDroyOxJvy8RN6gAMQ-Q0

Rohit Loomba1; Kris Kowdley2; Muhammad Y Sheikh3,4; Nomita Kim5; Anita Kohli6; Eric Lawitz7,8; Brenda Jeglinski9; Kelly Kutch9; Jose Manuel Trigo9; Patricia Mendez10; Margaret Koziel9; Stuart Kendrick11; Sumanta Mukherjee10; Mazen Noureddin12

Apr 19, 2026